Protagonist Therapeutics, Inc.

Protagonist Therapeutics is a discovery and development company focused on creating first-in-class oral and injectable peptide therapies. Its lead product, Icotyde, is an investigational oral peptide for moderate-to-severe plaque psoriasis in adults and pediatric patients aged 12 and older. Another key candidate, Rusfertide, is a hepcidin mimetic in Phase 3 development for polycythemia vera, a rare blood disorder. The company also has PN-881, an oral IL-17 antagonist in Phase 1 for immune-mediated skin diseases, and preclinical candidates for obesity, including PN-477, PN-458, and amylinR-based agonists. Additionally, it is developing PN-8047, an oral hepcidin mimetic small molecule, and an IL-4R alpha antagonist for atopic dermatitis and asthma.

Protagonist Therapeutics is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol PTGX. Its shares are traded in US dollars (USD). The company is headquartered in Newark, California, and operates primarily in the United States.

Protagonist Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on researching and developing innovative peptide-based therapies for various diseases, including dermatological, hematological, and metabolic conditions.

Protagonist Therapeutics is headquartered in Newark, California, United States. The company was incorporated in 2006 and has since been dedicated to discovering and developing novel peptide therapeutics. Its research and development efforts are centered in the US, targeting both common and rare diseases with significant unmet medical needs.

Protagonist Therapeutics has a diverse pipeline of peptide-based candidates. Icotyde is a first-in-class oral peptide for plaque psoriasis, while Rusfertide is an injectable hepcidin mimetic in Phase 3 for polycythemia vera. PN-881 is an oral IL-17 antagonist in Phase 1 for skin diseases. Preclinical programs include PN-477 and PN-458 for obesity, PN-8047 (oral hepcidin mimetic), an IL-4R alpha antagonist for atopic dermatitis and asthma, and amylinR-based agonists for obesity. These candidates target a range of therapeutic areas, from inflammatory conditions to metabolic disorders.